[EBS] Emergent Biosolutions, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 33.6 Change: 0.1 (0.3%)
Ext. hours: Change: 0 (0%)

chart EBS

Refresh chart

Strongest Trends Summary For EBS

EBS is in the long-term up 95% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -42.32% Sales Growth - Q/Q-57% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA3.86% ROE6.59% ROI4.26%
Current Ratio5.05 Quick Ratio4.03 Long Term Debt/Equity0.77 Debt Ratio0.15
Gross Margin74.31% Operating Margin12% Net Profit Margin7.71% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities11 M Cash From Investing Activities-9.08 M Cash From Operating Activities-65.87 M Gross Profit44.88 M
Net Profit-21.52 M Operating Profit-28.31 M Total Assets917.85 M Total Current Assets405.81 M
Total Current Liabilities80.3 M Total Debt251 M Total Liabilities379.97 M Total Revenue63.63 M
Technical Data
High 52 week73.24 Low 52 week42.42 Last close58.59 Last change-3.73%
RSI17.18 Average true range3.15 Beta0.82 Volume333.02 K
Simple moving average 20 days-12.99% Simple moving average 50 days-10.21% Simple moving average 200 days1.34%
Performance Data
Performance Week-9.28% Performance Month-17.79% Performance Quart-11.63% Performance Half9.25%
Performance Year26.93% Performance Year-to-date26.08% Volatility daily2.45% Volatility weekly5.49%
Volatility monthly11.25% Volatility yearly38.96% Relative Volume180.22% Average Volume401.43 K
New High New Low


2019-06-15 08:07:01 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-06-14 14:27:22 | Before You Buy Emergent BioSolutions Inc. NYSE:EBS, Consider Its Volatility

2019-06-10 08:07:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-06-05 13:20:58 | Emergent BioSolutions CEO on fighting drug pricing and the opioid epidemic

2019-06-04 18:58:00 | Don't Get Complacent: Cramer's 'Mad Money' Recap Tuesday 6/4/19

2019-06-04 16:05:00 | Emergent BioSolutions Announces FDA Approval of Change in Storage Conditions and Transfer of Manufacturing for Its Cholera Vaccine

2019-06-04 11:52:03 | Emergent EBS Wins HHS Contract to Supply VIGIV Product

2019-06-04 08:06:06 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-06-03 14:53:59 | What Emergent’s latest $535M contract means for national ‘smallpox franchise’

2019-06-03 06:30:00 | Emergent BioSolutions Awarded 10-Year HHS Contract Valued at Approximately $535 Million to Deliver Vaccinia Immune Globulin Intravenous VIGIV in Support of Smallpox Preparedness

2019-06-01 09:31:01 | Why Is Emergent Biosolutions EBS Down 23.4% Since Last Earnings Report?

2019-05-30 08:07:07 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-05-23 07:15:36 | You Might Like Emergent BioSolutions Inc. NYSE:EBS But Do You Like Its Debt?

2019-05-21 09:22:30 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-05-20 16:05:00 | Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe

2019-05-20 06:30:00 | Emergent BioSolutions to Participate in Series of Investor Conferences

2019-05-15 16:05:00 | Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile

2019-05-15 08:15:00 | 3 Top Healthcare Stocks to Buy in May

2019-05-14 11:47:47 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-05-09 06:30:00 | Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available

2019-05-08 16:54:00 | Emergent BioSolutions Negotiates for a Strong Second Half

2019-05-07 06:00:00 | 3 Top Biotech Stocks to Buy in May

2019-05-03 15:41:07 | Emergent EBS Earnings & Revenues Miss Estimates in Q1

2019-05-03 15:07:00 | Why Emergent BioSolutions Stock Is Tanking Today

2019-05-03 08:14:53 | Emergent BioSolutions Inc EBS Q1 2019 Earnings Call Transcript

2019-05-03 07:38:11 | New Strong Sell Stocks for May 3rd

2019-05-03 01:07:37 | Edited Transcript of EBS earnings conference call or presentation 2-May-19 9:00pm GMT

2019-05-02 19:25:11 | Emergent Biosolutions EBS Reports Q1 Loss, Misses Revenue Estimates

2019-05-02 18:18:30 | Emergent Biosolutions: 1Q Earnings Snapshot

2019-05-02 16:05:00 | Emergent BioSolutions Reports First Quarter 2019 Financial Results

2019-04-30 08:52:20 | What Are Analysts Saying About Emergent BioSolutions Inc.'s NYSE:EBS Earnings Trajectory?

2019-04-26 11:51:19 | Is Emergent Biosolutions Inc EBS A Good Stock To Buy ?

2019-04-25 10:34:02 | Emergent Biosolutions EBS Reports Next Week: Wall Street Expects Earnings Growth

2019-04-19 12:04:00 | FDA approves first generic naloxone nasal spray to treat opioid overdose

2019-04-18 07:22:22 | Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019

2019-04-17 11:01:03 | Emergent's EBS Chikungunya Vaccine Positive in Phase II Study

2019-04-16 06:30:00 | Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate

2019-04-10 10:08:03 | What Should We Expect From Emergent BioSolutions Inc.'s NYSE:EBS Earnings In The Year Ahead?

2019-04-09 10:59:02 | Emergent's EBS Strong Vaccine Portfolio to Fuel Growth

2019-04-09 10:50:40 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-03-26 08:24:25 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-03-23 09:30:01 | Emergent Biosolutions EBS Down 24.2% Since Last Earnings Report: Can It Rebound?

2019-03-20 11:24:03 | Emergent Begins Phase III Study on Anthrax Vaccine AV7909

2019-03-19 06:30:00 | Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

2019-03-14 11:21:02 | Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year

2019-03-11 07:15:11 | The Emergent BioSolutions NYSE:EBS Share Price Has Gained 111%, So Why Not Pay It Some Attention?

2019-02-28 16:45:43 | Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents

2019-02-25 16:20:00 | Emergent BioSolutions Looks to Break $1 Billion

2019-02-22 21:48:03 | Emergent BioSolutions Inc EBS Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-22 15:42:04 | Edited Transcript of EBS earnings conference call or presentation 21-Feb-19 10:00pm GMT